This study (22) presents a clinical trial evaluating a novel, fluorescently labeled anti-CEA antibody for intraoperative visualization in pancreatic cancer surgery, triggering an increased interest in clinically applying specific probes beyond traditional fluorescent agents in humans. The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.